Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Results of Operations and Financial Condition

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02

Results of Operations and Financial
Condition.

On May4, 2017, Agios Pharmaceuticals, Inc. (the Company) issued a
press release announcing its results for the quarter ended
March31, 2017 and other business highlights. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on
Form8-K.

The information in
this Form 8-K, including Exhibit 99.1, shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item9.01 Financial Statements and Exhibits.

(d)
Exhibits.

Exhibit No.

Description

99.1 Press release issued May4, 2017.


About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Recent Trading Information

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closed its last trading session down -0.41 at 46.79 with 952,874 shares trading hands.

An ad to help with our costs